Cytosorbents Corp (CTSO) Rating Reiterated by Brean Capital
March 10th, 2016 - By Maddie Sorensen
Cytosorbents (OTCMKTS:CTSO)‘s stock had its “buy” rating restated by Brean Capital in a report issued on Thursday, MarketBeat reports. They presently have a $24.00 price objective on the stock. Brean Capital’s price objective would indicate a potential upside of 373.37% from the company’s previous close.